WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 201450
CAS#: 236095-24-2 (HCl)
Description: Camsirubicin, also known as GPX-150, MNPR-201, and CNDO1011, is a synthetic non-cardiotoxic analogue of the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Anthracycline analogue GPX-150 intercalates DNA and impedes the activity of topoisomerase II, inducing single and double-stranded breaks in DNA; inhibiting DNA replication and/or repair, transcription, and protein synthesis; and activating tumor cell apoptosis.
MedKoo Cat#: 201450
Name: Camsirubicin HCl
CAS#: 236095-24-2 (HCl)
Chemical Formula: C27H33ClN2O9
Molecular Weight: 565.02
Elemental Analysis: C, 57.40; H, 5.89; Cl, 6.27; N, 4.96; O, 25.48
Camsirubicin HCl is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Related CAS #: 236095-24-2 (HCl) 236095-29-7 236095-26-4 (free base)
Synonym: MNPR-201; MNPR 201; MNPR201; CNDO1011; CNDO-1011; CNDO 1011; GPX150; GPX 150; GPX-150; GPX150 HCl; GPX150 hydrochloride; Camsirubicin HCl; Camsirubicin hydrochloride
IUPAC/Chemical Name: (8R,10S)-10-(((2S,4S,5R,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-7,8,9,10-tetrahydrotetracen-5(12H)-one hydrchloride
InChi Key: QVPRMGHPBJJSRU-KMIOROQSSA-N
InChi Code: InChI=1S/C27H32N2O9.ClH/c1-11-23(31)14(28)8-17(37-11)38-16-10-27(35,6-7-30)9-13-19(16)26(34)20-21(25(13)33)24(32)12-4-3-5-15(36-2)18(12)22(20)29;/h3-5,11,14,16-17,23,29-31,33-35H,6-10,28H2,1-2H3;1H/t11-,14-,16-,17+,23-,27-;/m0./s1
SMILES Code: O=C1C2=C(O)C(C[C@](CCO)(O)C[C@@H]3O[C@@H]4C[C@H](N)[C@@H](O)[C@H](C)O4)=C3C(O)=C2C(C5=C1C=CC=C5OC)=N.[H]Cl
The following data is based on the product molecular weight 565.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1. Zhang; Xini (Hoover, AL), Olson; Richard D. (Nampa, ID) 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them, United States Patent 5942605.
As of August 2010, GPX-150 is under Phase I clinical trials sponsored by Coronado Biosciences, Inc. This is a Phase 1 safety and dose escalation study to define the maximum tolerated dose (MTD) and identify the dose limiting toxicities (DLT) following IV administration of GPX-150 once every 3 weeks. Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment. (source: http://clinicaltrials.gov/ct2/show/NCT00710125).